

Acute Lymphoblastic Leukemia Market (Type: B-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Leukemia; Treatment: Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, and Immunotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Market Report | 2022-10-28 | 192 pages | Transparency Market Research

AVAILABLE LICENSES:

- Single User License \$5795.00
- Multi User License \$8795.00
- Global Site License \$11795.00

Report description:

Acute Lymphoblastic Leukemia Market - Scope of Report

TMR's report on the global acute lymphoblastic leukemia market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global acute lymphoblastic leukemia market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global acute lymphoblastic leukemia market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the acute lymphoblastic leukemia market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global acute lymphoblastic leukemia market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global acute

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

lymphoblastic leukemia market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global acute lymphoblastic leukemia market.

The report delves into the competitive landscape of the global acute lymphoblastic leukemia market. Key players operating in the global acute lymphoblastic leukemia market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global acute lymphoblastic leukemia market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market acute lymphoblastic leukemia.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants' insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:

WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service

Trade Data Sources

Trade Map
UN Comtrade
Trade Atlas

Company Information

OneSource Business Browser
Hoover's
Factiva
Bloomberg

Mergers & Acquisitions

Thomson Mergers & Acquisitions
MergerStat

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.

Helps in validating and strengthening secondary research findings

Further develops the analysis team's expertise and market understanding

Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers

Purchasing/Sourcing managers, technical personnel, distributors

Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets

Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC

Danfysik A/S

Hitachi, Ltd.

IBA Worldwide

Mevion Medical Systems, Inc.

Data Triangulation: Information culled from "Secondary & Primary Sources" is cross-checked with "TMR Knowledge Repository", which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others

Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Table of Contents:

1. Preface
 - 1.1. Market Definition and Scope
 - 1.2. Market Segmentation
 - 1.3. Key Research Objectives
 - 1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Lymphoblastic Leukemia Market
4. Market Overview
 - 4.1. Introduction
 - 4.1.1. Definition
 - 4.2. Overview
 - 4.3. Market Dynamics
 - 4.3.1. Drivers
 - 4.3.2. Restraints
 - 4.3.3. Opportunities
 - 4.4. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, 2017-2031
 - 4.4.1. Market Revenue Projections (US\$ Bn)
5. Key Insights
 - 5.1. Disease Prevalence & Incidence Rate globally
 - 5.2. Key Industry Events (mergers, acquisitions, partnerships, etc.)
 - 5.3. Pipeline Analysis
 - 5.4. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Type
 - 6.1. Introduction & Definition
 - 6.2. Key Findings/Developments
 - 6.3. Market Value Forecast, by Type, 2017-2031
 - 6.3.1. B-cell Acute Lymphoblastic Leukemia
 - 6.3.2. T-cell Lymphoblastic Leukemia
 - 6.4. Market Attractiveness Analysis, by Type
7. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment
 - 7.1. Introduction & Definition
 - 7.2. Key Findings/Developments
 - 7.3. Market Value Forecast, by Treatment, 2017-2031
 - 7.3.1. Chemotherapy
 - 7.3.2. Radiation Therapy
 - 7.3.3. Bone Marrow Transplant
 - 7.3.4. Targeted Therapy
 - 7.3.5. Immunotherapy
 - 7.4. Market Attractiveness Analysis, by Treatment
8. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End-user
 - 8.1. Introduction & Definition
 - 8.2. Key Findings/Developments
 - 8.3. Market Value Forecast, by End-user, 2017-2031
 - 8.3.1. Hospitals
 - 8.3.2. Clinics
 - 8.3.3. Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.4. Market Attractiveness Analysis, by End-user
- 9. Global Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Region
 - 9.1. Key Findings
 - 9.2. Market Value Forecast, by Region, 2017-2031
 - 9.2.1. North America
 - 9.2.2. Europe
 - 9.2.3. Asia Pacific
 - 9.2.4. Latin America
 - 9.2.5. Middle East & Africa
 - 9.3. Market Attractiveness Analysis, by Region
- 10. North America Acute Lymphoblastic Leukemia Market Analysis and Forecast
 - 10.1. Introduction
 - 10.1.1. Key Findings
 - 10.2. Market Value Forecast, by Type, 2017-2031
 - 10.2.1. B-cell Acute Lymphoblastic Leukemia
 - 10.2.2. T-cell Lymphoblastic Leukemia
 - 10.3. Market Value Forecast, by Treatment, 2017-2031
 - 10.3.1. Chemotherapy
 - 10.3.2. Radiation Therapy
 - 10.3.3. Bone Marrow Transplant
 - 10.3.4. Targeted Therapy
 - 10.3.5. Immunotherapy
 - 10.4. Market Value Forecast, by End-user, 2017-2031
 - 10.4.1. Hospitals
 - 10.4.2. Clinics
 - 10.4.3. Others
 - 10.5. Market Value Forecast, by Country, 2017-2031
 - 10.5.1. U.S.
 - 10.5.2. Canada
 - 10.6. Market Attractiveness Analysis
 - 10.6.1. By Type
 - 10.6.2. By Treatment
 - 10.6.3. By End-user
 - 10.6.4. By Country
- 11. Europe Acute Lymphoblastic Leukemia Market Analysis and Forecast
 - 11.1. Introduction
 - 11.1.1. Key Findings
 - 11.2. Market Value Forecast, by Type, 2017-2031
 - 11.2.1. B-cell Acute Lymphoblastic Leukemia
 - 11.2.2. T-cell Lymphoblastic Leukemia
 - 11.3. Market Value Forecast, by Treatment, 2017-2031
 - 11.3.1. Chemotherapy
 - 11.3.2. Radiation Therapy
 - 11.3.3. Bone Marrow Transplant
 - 11.3.4. Targeted Therapy
 - 11.3.5. Immunotherapy
 - 11.4. Market Value Forecast, by End-user, 2017-2031

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.1. Hospitals
- 11.4.2. Clinics
- 11.4.3. Others
- 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 11.5.1. Germany
 - 11.5.2. U.K.
 - 11.5.3. France
 - 11.5.4. Spain
 - 11.5.5. Italy
 - 11.5.6. Rest of Europe
- 11.6. Market Attractiveness Analysis
 - 11.6.1. By Type
 - 11.6.2. By Treatment
 - 11.6.3. By End-user
 - 11.6.4. By Country/Sub-region
- 12. Asia Pacific Acute Lymphoblastic Leukemia Market Analysis and Forecast
 - 12.1. Introduction
 - 12.1.1. Key Findings
 - 12.2. Market Value Forecast, by Type, 2017-2031
 - 12.2.1. B-cell Acute Lymphoblastic Leukemia
 - 12.2.2. T-cell Lymphoblastic Leukemia
 - 12.3. Market Value Forecast, by Treatment, 2017-2031
 - 12.3.1. Chemotherapy
 - 12.3.2. Radiation Therapy
 - 12.3.3. Bone Marrow Transplant
 - 12.3.4. Targeted Therapy
 - 12.3.5. Immunotherapy
 - 12.4. Market Value Forecast, by End-user, 2017-2031
 - 12.4.1. Hospitals
 - 12.4.2. Clinics
 - 12.4.3. Others
 - 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 12.5.1. China
 - 12.5.2. Japan
 - 12.5.3. India
 - 12.5.4. Australia & New Zealand
 - 12.5.5. Rest of Asia Pacific
 - 12.6. Market Attractiveness Analysis
 - 12.6.1. By Type
 - 12.6.2. By Treatment
 - 12.6.3. By End-user
 - 12.6.4. By Country/Sub-region
- 13. Latin America Acute Lymphoblastic Leukemia Market Analysis and Forecast
 - 13.1. Introduction
 - 13.1.1. Key Findings
 - 13.2. Market Value Forecast, by Type, 2017-2031
 - 13.2.1. B-cell Acute Lymphoblastic Leukemia

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.2.2. T-cell Lymphoblastic Leukemia
- 13.3. Market Value Forecast, by Treatment, 2017-2031
 - 13.3.1. Chemotherapy
 - 13.3.2. Radiation Therapy
 - 13.3.3. Bone Marrow Transplant
 - 13.3.4. Targeted Therapy
 - 13.3.5. Immunotherapy
- 13.4. Market Value Forecast, by End-user, 2017-2031
 - 13.4.1. Hospitals
 - 13.4.2. Clinics
 - 13.4.3. Others
- 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 13.5.1. Brazil
 - 13.5.2. Mexico
 - 13.5.3. Rest of Latin America
- 13.6. Market Attractiveness Analysis
 - 13.6.1. By Type
 - 13.6.2. By Treatment
 - 13.6.3. By End-user
 - 13.6.4. By Country/Sub-region
- 14. Middle East & Africa Acute Lymphoblastic Leukemia Market Analysis and Forecast
 - 14.1. Introduction
 - 14.1.1. Key Findings
 - 14.2. Market Value Forecast, by Type, 2017-2031
 - 14.2.1. B-cell Acute Lymphoblastic Leukemia
 - 14.2.2. T-cell Lymphoblastic Leukemia
 - 14.3. Market Value Forecast, by Treatment, 2017-2031
 - 14.3.1. Chemotherapy
 - 14.3.2. Radiation Therapy
 - 14.3.3. Bone Marrow Transplant
 - 14.3.4. Targeted Therapy
 - 14.3.5. Immunotherapy
 - 14.4. Market Value Forecast, by End-user, 2017-2031
 - 14.4.1. Hospitals
 - 14.4.2. Clinics
 - 14.4.3. Others
 - 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
 - 14.5.1. GCC Countries
 - 14.5.2. South Africa
 - 14.5.3. Rest of Middle East & Africa
 - 14.6. Market Attractiveness Analysis
 - 14.6.1. By Type
 - 14.6.2. By Treatment
 - 14.6.3. By End-user
 - 14.6.4. By Country/Sub-region
- 15. Competition Landscape
 - 15.1. Market Player - Competition Matrix (by tier and size of companies)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.2. Market Share Analysis, by Company, 2021
- 15.3. Company Profiles
 - 15.3.1. Amgen, Inc.
 - 15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.1.2. Company Financials
 - 15.3.1.3. Growth Strategies
 - 15.3.1.4. SWOT Analysis
 - 15.3.2. Bristol-Myers Squibb Company
 - 15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.2.2. Company Financials
 - 15.3.2.3. Growth Strategies
 - 15.3.2.4. SWOT Analysis
 - 15.3.3. Celgene Corporation
 - 15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.3.2. Company Financials
 - 15.3.3.3. Growth Strategies
 - 15.3.3.4. SWOT Analysis
 - 15.3.4. Erytech Pharma, Inc.
 - 15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.4.2. Company Financials
 - 15.3.4.3. Growth Strategies
 - 15.3.4.4. SWOT Analysis
 - 15.3.5. F. Hoffmann-La Roche Ltd.
 - 15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.5.2. Company Financials
 - 15.3.5.3. Growth Strategies
 - 15.3.5.4. SWOT Analysis
 - 15.3.6. Kite Pharma, Inc.
 - 15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.6.2. Company Financials
 - 15.3.6.3. Growth Strategies
 - 15.3.6.4. SWOT Analysis
 - 15.3.7. Novartis AG
 - 15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.7.2. Company Financials
 - 15.3.7.3. Growth Strategies
 - 15.3.7.4. SWOT Analysis
 - 15.3.8. Pfizer, Inc.
 - 15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.8.2. Company Financials
 - 15.3.8.3. Growth Strategies
 - 15.3.8.4. SWOT Analysis
 - 15.3.9. Sanofi
 - 15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
 - 15.3.9.2. Company Financials
 - 15.3.9.3. Growth Strategies
 - 15.3.9.4. SWOT Analysis

15.3.10. Spectrum Pharmaceuticals, Inc.

15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

15.3.10.2. Company Financials

15.3.10.3. Growth Strategies

15.3.10.4. SWOT Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Acute Lymphoblastic Leukemia Market (Type: B-cell Acute Lymphoblastic Leukemia and T-cell Lymphoblastic Leukemia; Treatment: Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, and Immunotherapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Market Report | 2022-10-28 | 192 pages | Transparency Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5795.00
	Multi User License	\$8795.00
	Global Site License	\$11795.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-06-25

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com